Advertisement
Advertisement
BCAX
Bicara Therapeutics Inc. Common Stock
15.36
USDSponsored
+0.26
+1.73%
Feb 06, 15:59 UTC -5
Closed
After-Market
15.23
-0.13
-0.85%
BCAX Earnings Reports
Positive Surprise Ratio
BCAX beat 1 of 5 last estimates.
20%
Next Report
Date of Next Report
Mar 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.68
Implied change from Q3 25 (Revenue/ EPS)
--
/+1.49%
Implied change from Q4 24 (Revenue/ EPS)
--
/+74.36%
Bicara Therapeutics Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, BCAX reported earnings of -0.67 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -19.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an increase of 1.49% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Bicara Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bicara Therapeutics Inc. Common Stock reported EPS of -$0.67, missing estimates by -19.6%, and revenue of $0.00, 0% as expectations.
How did the market react to Bicara Therapeutics Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.85%, changed from $14.64 before the earnings release to $13.93 the day after.
When is Bicara Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 24, 2026.
What are the forecasts for Bicara Therapeutics Inc. Common Stock's next earnings report?
Based on 13
analysts, Bicara Therapeutics Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement